Literature DB >> 18558878

Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports.

David P Gallagher1, Jennifer Kieran, Gerard Sheehan, John Lambert, Niall Mahon, Patrick W G Mallon.   

Abstract

We describe 2 cases of symptomatic ventricular tachycardia associated with prolonged QT interval. Both patients were infected with the human immunodeficiency virus and were receiving treatment with ritonavir-boosted atazanavir and methadone. Discontinuation of atazanavir in both cases resulted in a reduction in the QT interval and cessation of arrhythmia. We concluded that atazanavir contributed to prolonged corrected QT interval and subsequent ventricular tachycardia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558878     DOI: 10.1086/589869

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.

Authors:  Sheng-na Han; Xiao-yan Sun; Zhao Zhang; Li-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-03-23       Impact factor: 6.150

2.  Life-threatening cardiac arrhythmias due to drug-induced QT prolongation : A retrospective study over 6 years from a medical intensive care unit.

Authors:  G Michels; M Kochanek; R Pfister
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-09-04       Impact factor: 0.840

3.  Long-term treatment of patients with HIV-1: the role of atazanavir.

Authors:  Miguel Ángel Artacho; Pablo Barreiro; José Vicente Fernández-Montero
Journal:  HIV AIDS (Auckl)       Date:  2010-09-13

Review 4.  A systematic review of the cardiotoxicity of methadone.

Authors:  Samira Alinejad; Toba Kazemi; Nasim Zamani; Robert S Hoffman; Omid Mehrpour
Journal:  EXCLI J       Date:  2015-05-05       Impact factor: 4.068

Review 5.  A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.

Authors:  Wen-Liang Yu; Han Siong Toh; Chia-Te Liao; Wei-Ting Chang
Journal:  Cardiovasc Drugs Ther       Date:  2020-06-17       Impact factor: 3.727

6.  Monomorphic ventricular tachycardia due to protease inhibitor intoxication by atazanavir.

Authors:  Byunghyun Kim; Kyung Su Kim
Journal:  Clin Exp Emerg Med       Date:  2018-04-30

7.  Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.

Authors:  Zheng Zequn; W U Yujia; Q I A N Dingding; L I A N Jiangfang
Journal:  Eur J Pharmacol       Date:  2020-12-17       Impact factor: 4.432

8.  Role of atazanavir in the treatment of HIV infection.

Authors:  Pablo Rivas; Judit Morello; Carolina Garrido; Sonia Rodríguez-Nóvoa; Vincent Soriano
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.